Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Liang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5038-694X; OpenAlex author ID A5007646187. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. CAR-Macrophage Cell Therapy: A New Era of Hope for Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-25-1201↗
  2. A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer. First author DOI 10.1158/1078-0432.ccr-23-2098↗
  3. Activation of Vitamin D/VDR Signaling Reverses Gemcitabine Resistance of Pancreatic Cancer Cells Through Inhibition of MUC1 Expression. First author DOI 10.1007/s10620-023-07931-3↗
  4. Vitamin D: Promises on the Horizon and Challenges Ahead for Fighting Pancreatic Cancer. First author DOI 10.3390/cancers13112716↗
  5. Pancreatic Acinar-to-Ductal Metaplasia and Pancreatic Cancer. Co-author DOI 10.1007/978-1-4939-8879-2_26↗
  6. Novel and emerging innate immune therapeutic targets for pancreatic cancer. Co-author DOI 10.1080/14728222.2018.1538361↗
  7. COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/mc.22520↗
  8. The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-16-1064↗
  9. HGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes. Co-author DOI 10.1038/onc.2016.14↗
  10. NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11010-015-2535-7↗
  11. Hippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progression. Co-author DOI 10.18632/oncotarget.5772↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daoyan Wei · 7 shared papers, 2017–2025 · strength 1.30
  2. Xiangsheng Zuo · 4 shared papers, 2021–2025 · strength 0.96
  3. Robert S. Bresalier · 4 shared papers, 2021–2025 · strength 0.96
  4. Yi Liu · 2 shared papers, 2023–2025 · strength 0.49
  5. Xiling Shen · 1 shared paper, 2025 · strength 0.30
  6. Anirban Maitra · 1 shared paper, 2024 · strength 0.28
  7. Dacheng Xie · 3 shared papers, 2015–2019 · strength 0.28
  8. Peiying Yang · 1 shared paper, 2023 · strength 0.18
  9. Ming Quan · 3 shared papers, 2015–2017 · strength 0.17
  10. Jiujie Cui · 3 shared papers, 2015–2017 · strength 0.17
  11. Imad Shureiqi · 1 shared paper, 2018 · strength 0.12
  12. Yong Gao · 2 shared papers, 2015–2017 · strength 0.12
  13. Keping Xie · 2 shared papers, 2015–2017 · strength 0.12
  14. Nan You · 1 shared paper, 2017 · strength 0.07
  15. Lu Zheng · 1 shared paper, 2017 · strength 0.07
  16. Xiaobing Huang · 1 shared paper, 2017 · strength 0.07
  17. Qingyong Ma · 1 shared paper, 2017 · strength 0.07
  18. Kun Guo · 1 shared paper, 2017 · strength 0.07
  19. Ke Xie · 1 shared paper, 2016 · strength 0.06
  20. Yixin Zhang · 1 shared paper, 2015 · strength 0.04
  21. Xiaorong Liu · 1 shared paper, 2015 · strength 0.04
  22. Guoxiong Zhou · 1 shared paper, 2015 · strength 0.04
  23. Ji Li · 1 shared paper, 2015 · strength 0.04
  24. Chunhua Wan · 1 shared paper, 2015 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.